Ensysce Biosciences Extends MPAR Overdose Protection Patent in Taiwan to 2042
ENSC•Ensysce Biosciences secured a Taiwan patent extension for its MPAR overdose protection platform, expanding US Patent No. 12,599,578 and ensuring IP coverage through 2042 in that jurisdiction. MPAR has Breakthrough Therapy designation and clinical data show PF614-MPAR delivers effective pain relief while preventing excessive opioid release.
1. Patent Extension Details
Ensysce Biosciences announced that the Taiwan Intellectual Property Office has issued a patent titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof," which extends MPAR patent coverage through 2042 in Taiwan and builds on US Patent No. 12,599,578 issued on April 14, 2026.
2. Regulatory and Clinical Milestones
MPAR has been granted Breakthrough Therapy designation by the FDA. Clinical studies demonstrate that PF614-MPAR provides targeted analgesia when used as directed and prevents excessive opioid release when multiple doses are taken, underscoring the technology’s overdose protection properties.
3. Pipeline Expansion and Next Steps
Ensysce is applying MPAR beyond opioids to amphetamines and methadone for safer treatments in pain, ADHD and opioid use disorder. Supported by National Institute on Drug Abuse funding, the company is advancing PF614 and PF614-MPAR into late-stage clinical trials alongside its TAAP abuse-deterrent platform.
